Qiagen (NYSE:QGEN) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Qiagen (NYSE:QGEN) from a hold rating to a buy rating in a report released on Sunday.

Other research analysts also recently issued reports about the stock. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 15th. Barclays reissued an “overweight” rating and issued a $55.00 target price (up previously from $53.00) on shares of Qiagen in a report on Monday, December 15th. Finally, Citigroup lowered Qiagen from a “buy” rating to a “neutral” rating and lowered their target price for the company from $55.00 to $50.00 in a report on Thursday, December 11th. Two equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $49.61.

Qiagen Trading Up 1.4%

NYSE:QGEN opened at $45.57 on Friday. The company has a market cap of $10.13 billion, a PE ratio of 24.77, a P/E/G ratio of 2.33 and a beta of 0.68. The business’s 50 day moving average is $46.32 and its two-hundred day moving average is $47.13. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45. Qiagen has a 52 week low of $37.63 and a 52 week high of $51.88.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.03. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The business had revenue of $532.58 million for the quarter, compared to analyst estimates of $525.68 million. During the same period in the prior year, the company posted $0.57 EPS. The business’s revenue was up 6.2% compared to the same quarter last year. On average, analysts predict that Qiagen will post 2.26 EPS for the current year.

Institutional Investors Weigh In On Qiagen

Hedge funds have recently made changes to their positions in the business. Allworth Financial LP boosted its position in shares of Qiagen by 23.2% during the third quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock worth $61,000 after buying an additional 256 shares during the period. Danske Bank A S bought a new stake in Qiagen during the 3rd quarter valued at $36,000. Advisory Services Network LLC acquired a new position in Qiagen during the 3rd quarter worth $64,000. Dark Forest Capital Management LP bought a new position in shares of Qiagen in the third quarter worth $283,000. Finally, XTX Topco Ltd bought a new position in shares of Qiagen in the third quarter worth $749,000. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.